Proceedings of MATSUS Fall 2023 Conference (MATSUSFall23)
Publication date: 18th July 2023
Introduction: We use ELectroPHoretic Implants (ELPHIs) for triggered drug release of transiently charged chemotherapeutics, which rely on a precise and electronically controllable drug delivery mechanism. The used devices allow long-lasting device durability and precise electrical control over delivery rates. Continuous ELPHI-mediated gemcitabine administration efficiently reduces tumor size compared to drop casting, maintaining a high local drug concentration over 24 hours. Building on this success, we plan to translate this progress into implantable ELPHI device designs for in vivo studies using established technology for combination therapies such as chemoimmunotherapy.
Aim: We aim to develop a powerful multi-level cancer treatment system using an in vivo implant. This system will synergize the local tumor-reducing effects achieved by the controlled long-term release of potent chemotherapeutics via ELPHI. By utilizing timed, high drug concentrations for efficient local tumor shrinkage, our goal is to decrease tumor size, improve overall survival, and reduce tumor recurrence and tumor antigen presentation.
Methods: Implantation of a chemo-ELPHI in a mouse flank will be followed by foreign body response (FBR) measurement using immunohistochemistry (IHC) and flow cytometry. We use a mouse model that offers a controlled immune response and inject tumor cells near the ELPHI implant site, followed by chemo-ELPHI treatment. Pharmacokinetic studies utilizing LC-MS will assess implant performance and optimize drug concentrations locally while minimizing systemic effects.
Expected Results: With the respected methods, we can estimate the FBR and implant performance. These are essential steps to build up towards the combinational treatment with immune checkpoint inhibitors- which has the potential to treat tumors both locally and distally.